Evidence map›Paper›PMID 39498678›Full record

ArticleJournal of extracellular vesicles2024

A novel multiplexed immunoassay for surface-exposed proteins in plasma extracellular vesicles.

Emma Tordoff, Jillian Allen, Katya Elgart, Ahmed Elsherbini, Vrinda Kalia, Haotian Wu, Erden Eren, Dimitrios Kapogiannis, Olesia Gololobova, Kenneth Witwer and 2 more

Abstract read
In one paragraph

Article in Journal of extracellular vesicles, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emma TordoffNeuroDex, Inc., Natick, Massachusetts, USA.
Jillian AllenNeuroDex, Inc., Natick, Massachusetts, USA.
Katya ElgartNeuroDex, Inc., Natick, Massachusetts, USA.ORCID 0000-0002-4852-3172
Ahmed ElsherbiniNeuroDex, Inc., Natick, Massachusetts, USA.
Vrinda KaliaDepartment of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, New York, USA.
Haotian WuDepartment of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, New York, USA.
Erden ErenLaboratory of Neurosciences, Intramural Research Program, National Institute on Aging/National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.ORCID 0000-0002-5190-9500
Dimitrios KapogiannisLaboratory of Neurosciences, Intramural Research Program, National Institute on Aging/National Institutes of Health (NIA/NIH), Baltimore, Maryland, USA.
Olesia GololobovaDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, Maryland, USA.
Kenneth WitwerDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, Maryland, USA.
Olga VolpertNeuroDex, Inc., Natick, Massachusetts, USA.ORCID 0000-0003-1381-5543
Erez EitanNeuroDex, Inc., Natick, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small membranous extracellular vesicles (EV) incorporate proteins and nucleic acids from the parent cell. Proteins exposed on EV surface are dictated by cellular origin and biogenesis pathway. To better understand the EV origin and function, it is important to develop methods that reveal surface protein composition of heterogeneous EV populations in culture supernatants and in biofluids. Tetraspanins CD9, CD63, and CD81 are common and abundant EV markers. However, their relative enrichment (profile) on EVs of specific cellular origins is not fully elucidated. We introduce LuminEV, a novel version of the Luminex assay for the multiplexed analysis of EV surface proteins. Optimized LuminEV reagents enable direct, specific, and sensitive measurements of EV markers in biofluids and in culture supernatants, bypassing EV isolation step. LuminEV assay for CD9, CD63, and CD81 was validated by comparing simplex and multiplex measurements, establishing linearity, spike-in recovery, inter- and intra-assay precision, and reproducibility between operators. LuminEV measurements of CD9, CD63, and CD81 in conditioned media from 15 cell lines revealed strong variations between cell types and showed high sensitivity, which enabled EV detection without prior concentration. Using tetraspanin levels as a readout, we noted suppression and induction of EV release from the cultured cells by GW6869 and monensin. Measurement of EV CD9, CD63, and CD81 in blood plasma from 70 disease-free donors showed respective abundance of 72, 16, and 12%. CD63 displayed weak, albeit significant, negative correlation with age and was slightly lower in female samples. The assay was then used to detect cell type-specific EV surface markers, including CD235a (erythrocytes), GAP43 (neurons), and CD68 (macrophages), and to detect differences in tetraspanin profiles between healthy and diseased donors. In summary, LuminEV offers robust and sensitive approach for multiplexed assessment of EV surface proteins, to facilitate the research into EV biology, biomarker, and therapeutic applications.

Indexed as

Extracellular VesiclesTetraspanin 28Tetraspanin 29Tetraspanin 30BiomarkersFemaleHumansImmunoassayMembrane ProteinsBiomarkersCD63 protein, humanCD81 protein, humanCD9 protein, humanMembrane ProteinsTetraspanin 28Tetraspanin 29Tetraspanin 30assay validationextracellular vesiclessurface marker analysistetraspanin composition

Identifiers

PMID39498678
PMCPMC11535882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.